CRC
MCID: CLR023
MIFTS: 100

Colorectal Cancer (CRC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Colorectal Cancer

MalaCards integrated aliases for Colorectal Cancer:

Name: Colorectal Cancer 57 12 72 36 29 29 54 6 42 3 15 37 62 17 70
Colon Cancer 57 12 72 54 6 3 15
Colorectal Carcinoma 12 54 15 17 70
Colon Carcinoma 12 54 15 17 70
Colorectal Cancer, Susceptibility to 57 29 6
Carcinoma of Colon 12 29 6
Colorectal Cancer with Chromosomal Instability, Somatic 57 6
Colon Cancer, Susceptibility to 57 6
Colon Cancer, Somatic 57 13
Colorectal Neoplasms 44 70
Colonic Neoplasms 44 70
Crc 57 72
Colon Cancer, Advanced, Somatic 57
Cancer, Colorectal, Somatic 39
Colorectal Cancer, Somatic 57
Malignant Tumor of Colon 70
Colorectal Carcinomas 15
Colorectal Neoplasm 17
Colorectal Cancers 15
Cancer, Colorectal 39
Colonic Carcinoma 12
Colonic Neoplasm 17
Colon Cancers 15
Cancer, Colon 39

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
somatic mutation
autosomal dominant


HPO:

31
colorectal cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:



External Ids:

OMIM® 57 114500
KEGG 36 H00020
ICD9CM 34 153
ICD10 32 C18 C18.9
UMLS 70 C0007102 C0009375 C0009402 more

Summaries for Colorectal Cancer

PubMed Health : 62 About colorectal cancer: Colorectal (bowel) cancer is one of the more common forms of cancer in many countries, including Germany. The name "colorectal cancer" is used to describe bowel cancer that starts in the colon (the large intestine) or the rectum. Cancer of the small intestine is very rare. Colorectal cancer almost always develops from growths called colorectal polyps that form in the lining of the colon. But by no means do all polyps become cancerous – and if a polyp does become cancerous, it takes many years. One way to prevent colorectal cancer is to have a colonoscopy, which also allows doctors to remove polyps. Having colorectal cancer can be a life-changing experience. What happens after the diagnosis has been made will depend on various factors, including the stage of the cancer. In early-stage colorectal cancer, the tumor just needs to be surgically removed. In advanced stages, additional treatments may be considered, such as chemotherapy or radiation therapy. In Germany, high-quality medical care is available for people who have cancer. There are also a number of sources of support, for instance to help cope with the disease emotionally and make it easier to go back to work.

MalaCards based summary : Colorectal Cancer, also known as colon cancer, is related to lynch syndrome and adenoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Colorectal Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Colorectal cancer and MicroRNAs in cancer. The drugs Erythromycin and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include colon, rectum and liver, and related phenotypes are renal cell carcinoma and neoplasm of the stomach

Disease Ontology : 12 A large intestine cancer that is located in the colon and/or located in the rectum.

OMIM® : 57 Colorectal cancer is a heterogeneous disease that is common in both men and women. In addition to lifestyle and environmental risk factors, gene defects can contribute to an inherited predisposition to CRC. CRC is caused by changes in different molecular pathogenic pathways, such as chromosomal instability, CpG island methylator phenotype, and microsatellite instability. Chromosome instability is the most common alteration and is present in almost 85% of all cases (review by Schweiger et al., 2013). (114500) (Updated 05-Apr-2021)

MedlinePlus : 42 The colon and rectum are part of the large intestine. Colorectal cancer occurs when tumors form in the lining of the large intestine. It is common in both men and women. The risk of developing colorectal cancer rises after age 50. You're also more likely to get it if you have colorectal polyps, a family history of colorectal cancer, ulcerative colitis or Crohn's disease, eat a diet high in fat, or smoke. Symptoms of colorectal cancer include Diarrhea or constipation A feeling that your bowel does not empty completely Blood (either bright red or very dark) in your stool Stools that are narrower than usual Frequent gas pains or cramps, or feeling full or bloated Weight loss with no known reason Fatigue Nausea or vomiting Because you may not have symptoms at first, it's important to have screening tests. Everyone over 50 should get screened. Tests include colonoscopy and tests for blood in the stool. Treatments for colorectal cancer include surgery, chemotherapy, radiation, or a combination. Surgery can usually cure it when it is found early. NIH: National Cancer Institute

CDC : 3 Colorectal cancer is cancer that occurs in the colon or rectum. Sometimes it is called colon cancer, for short. As the drawing shows, the colon is the large intestine or large bowel. The rectum is the passageway that connects the colon to the anus. Sometimes abnormal growths, called polyps, form in the colon or rectum. Over time, some polyps may turn into cancer. Screening tests can find polyps so they can be removed before turning into cancer. Screening also helps find colorectal cancer at an early stage, when treatment works best.

KEGG : 36 Colorectal cancer (CRC) is the second largest cause of cancer-related deaths in Western countries. CRC arises from the colorectal epithelium as a result of the accumulation of genetic alterations in defined oncogenes and tumour suppressor genes (TSG). Two major mechanisms of genomic instability have been identified in sporadic CRC progression. The first, known as chromosomal instability (CIN), results from a series of genetic changes that involve the activation of oncogenes such as K-ras and inactivation of TSG such as p53, DCC/Smad4, and APC. The second, known as microsatellite instability (MSI), results from inactivation of the DNA mismatch repair genes MLH1 and/or MSH2 by hypermethylation of their promoter, and secondary mutation of genes with coding microsatellites, such as transforming growth factor receptor II (TGF-RII) and BAX. Hereditary syndromes have germline mutations in specific genes (mutation in the tumour suppressor gene APC on chromosome 5q in FAP, mutated DNA mismatch repair genes in HNPCC).

UniProtKB/Swiss-Prot : 72 Colorectal cancer: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

Wikipedia : 73 Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development... more...

Related Diseases for Colorectal Cancer

Diseases in the Colorectal Cancer family:

Colorectal Cancer 1 Colorectal Cancer 2
Colorectal Cancer 3 Colorectal Cancer 5
Colorectal Cancer 6 Colorectal Cancer 7
Colorectal Cancer 8 Colorectal Cancer 9
Colorectal Cancer 10 Colorectal Cancer 11
Colorectal Cancer 12 Familial Colorectal Cancer
Familial Colorectal Cancer Type X

Diseases related to Colorectal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1659)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 36.3 TP53 PTPRJ PIK3CA NRAS MLH3 MCC
2 adenoma 34.0 TP53 PIK3CA CTNNB1 BRAF AXIN2 APC
3 familial adenomatous polyposis 34.0 TP53 PLA2G2A MCC CTNNB1 AXIN2 APC
4 familial colorectal cancer 33.8 TP53 PLA2G2A BRAF APC
5 colon adenocarcinoma 33.7 TP53 PIK3CA CTNNB1 BRAF BAX APC
6 adenocarcinoma 33.7 TP53 PIK3CA FGFR3 CTNNB1 BRAF BAX
7 endometrial cancer 33.5 TP53 PIK3CA NRAS MLH3 CTNNB1 BRAF
8 cowden syndrome 33.4 TP53 PIK3CA FLCN CTNNB1 APC AKT1
9 hepatocellular carcinoma 33.4 TP53 PIK3CA PDGFRL NRAS CTNNB1 BRAF
10 colorectal adenocarcinoma 33.3 TP53 CTNNB1 BRAF APC
11 gastric cancer 33.2 TP53 PIK3CA NRAS CTNNB1 BRAF BAX
12 colonic disease 33.1 TP53 CTNNB1 APC AKT1
13 lung cancer susceptibility 3 33.0 TP53 PIK3CA NRAS FGFR3 CTNNB1 BRAF
14 esophageal cancer 32.9 TP53 PIK3CA EP300 DCC CTNNB1 BAX
15 pancreatic cancer 32.9 TP53 PIK3CA EP300 CTNNB1 BUB1 BRAF
16 neuroblastoma 32.8 TP53 PLA2G2A PIK3CA NRAS FGFR3 CTNNB1
17 bladder cancer 32.8 TP53 PIK3CA NRAS FGFR3 CTNNB1 BRAF
18 colorectal adenoma 32.7 TP53 CTNNB1 APC
19 serrated polyposis syndrome 32.7 BRAF APC
20 glioblastoma 32.6 TP53 PIK3CA NRAS BRAF BAX AKT1
21 renal cell carcinoma, nonpapillary 32.6 TP53 PIK3CA NRAS FLCN BRAF BAX
22 sarcoma 32.5 TP53 PIK3CA NRAS FGFR3 EP300 CTNNB1
23 cervical cancer 32.5 TP53 PIK3CA FGFR3 EP300 CTNNB1 BAX
24 gastric adenocarcinoma 32.4 TP53 PIK3CA NRAS CTNNB1 BRAF APC
25 cholangiocarcinoma 32.4 TP53 PIK3CA CTNNB1 BRAF APC AKT1
26 gastrointestinal stromal tumor 32.4 TP53 FGFR3 EP300 BRAF APC AKT1
27 rectum adenocarcinoma 32.3 TP53 PIK3CA CTNNB1
28 skin carcinoma 32.3 TP53 PIK3CA NRAS CTNNB1 BRAF AKT1
29 lymphoma, non-hodgkin, familial 32.3 TP53 PIK3CA NRAS BRAF BAX APC
30 in situ carcinoma 32.3 TP53 PIK3CA CTNNB1 AKT1
31 myeloma, multiple 32.3 TP53 PIK3CA NRAS FGFR3 CTNNB1 BRAF
32 brain cancer 32.3 TP53 PIK3CA NRAS CTNNB1 BRAF APC
33 medulloblastoma 32.2 TP53 PIK3CA NRAS EP300 CTNNB1 AXIN2
34 nasopharyngeal carcinoma 32.2 TP53 PIK3CA NRAS CTNNB1 BAX AKT1
35 leukemia, acute myeloid 32.1 TP53 PIK3CA NRAS EP300 CTNNB1 AKT1
36 squamous cell carcinoma 32.1 TP53 PIK3CA FGFR3 EP300 CTNNB1 BRAF
37 squamous cell carcinoma, head and neck 32.0 TP53 PIK3CA FGFR3 EP300 CTNNB1 BRAF
38 villous adenoma 32.0 TP53 BRAF APC
39 intestinal benign neoplasm 32.0 TP53 PIK3CA CTNNB1 AXIN2 APC AKT1
40 peutz-jeghers syndrome 32.0 TP53 CTNNB1 APC
41 kidney cancer 32.0 TP53 PIK3CA FLCN AKT1
42 pancreatic adenocarcinoma 31.9 TP53 PIK3CA CTNNB1 BRAF AKT1
43 leukemia, chronic lymphocytic 31.9 TP53 NRAS BRAF BAX APC AKT1
44 rhabdomyosarcoma 31.9 TP53 PIK3CA NRAS FGFR3 CTNNB1 BUB1B
45 lung squamous cell carcinoma 31.8 TP53 PIK3CA FGFR3 EP300 CTNNB1 BRAF
46 bladder urothelial carcinoma 31.7 TP53 PIK3CA NRAS FGFR3 EP300 CTNNB1
47 gallbladder cancer 31.7 TP53 PIK3CA CTNNB1 AKT1
48 hepatoblastoma 31.7 TP53 CTNNB1 AXIN2 APC AKT1
49 rasopathy 31.6 TP53 PIK3CA NRAS FGFR3 CTNNB1 BRAF
50 renal cell carcinoma, papillary, 1 31.6 TP53 PIK3CA NRAS FLCN FGFR3 CTNNB1

Comorbidity relations with Colorectal Cancer via Phenotypic Disease Network (PDN): (show all 21)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Ascending Colon Cancer
Cecal Benign Neoplasm Deficiency Anemia
Descending Colon Cancer Familial Atrial Fibrillation
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Intestinal Obstruction
Intestinal Perforation Iron Deficiency Anemia
Neutropenia Paralytic Ileus
Protein-Energy Malnutrition Rectosigmoid Junction Neoplasm
Small Intestine Cancer Splenic Flexure Cancer
Transverse Colon Cancer

Graphical network of the top 20 diseases related to Colorectal Cancer:



Diseases related to Colorectal Cancer

Symptoms & Phenotypes for Colorectal Cancer

Human phenotypes related to Colorectal Cancer:

31
# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 31 HP:0005584
2 neoplasm of the stomach 31 HP:0006753
3 transitional cell carcinoma of the bladder 31 HP:0006740
4 uterine leiomyosarcoma 31 HP:0002891
5 hereditary nonpolyposis colorectal carcinoma 31 HP:0006716

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Neoplasia:
colorectal cancer

Clinical features from OMIM®:

114500 (Updated 05-Apr-2021)

UMLS symptoms related to Colorectal Cancer:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Colorectal Cancer according to GeneCards Suite gene sharing:

26 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.84 BRAF PIK3CA
2 Decreased viability GR00055-A-2 10.84 BRAF PIK3CA
3 Decreased viability GR00221-A-1 10.84 BUB1B AKT1 FGFR3 NRAS PIK3CA PDGFRL
4 Decreased viability GR00221-A-2 10.84 BUB1B AKT1 DCC FGFR3 EP300 PIK3CA
5 Decreased viability GR00221-A-3 10.84 BUB1B AKT1 DCC FGFR3 NRAS
6 Decreased viability GR00221-A-4 10.84 BRAF AKT1 DCC PIK3CA
7 Decreased viability GR00249-S 10.84 BRAF BUB1 AKT1 FGFR3
8 Decreased viability GR00301-A 10.84 BRAF BUB1 BUB1B MLH3
9 Decreased viability GR00381-A-1 10.84 BRAF
10 Decreased viability GR00402-S-2 10.84 PIK3CA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.83 PLA2G2A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.83 APC
13 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.83 BRAF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.83 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.83 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-203 9.83 PLA2G2A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.83 AKT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.83 BRAF CTNNB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.83 AKT1 PIK3CA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.83 PLA2G2A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.83 AKT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.83 AKT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.83 PLA2G2A
24 Decreased cell migration GR00055-A-1 9.62 AKT1 FGFR3
25 Decreased cell migration GR00055-A-3 9.62 BRAF PIK3CA
26 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 APC AXIN2 BRAF BUB1 MCC
27 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.85 CTNNB1

MGI Mouse Phenotypes related to Colorectal Cancer:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.52 AKT1 APC AXIN2 BAX BRAF BUB1
2 growth/size/body region MP:0005378 10.49 AKT1 APC AXIN2 BAX BRAF BUB1
3 behavior/neurological MP:0005386 10.44 AKT1 APC BAX BRAF BUB1 BUB1B
4 homeostasis/metabolism MP:0005376 10.43 AKT1 APC BAX BRAF BUB1 BUB1B
5 immune system MP:0005387 10.42 AKT1 APC BAX BRAF BUB1 BUB1B
6 hematopoietic system MP:0005397 10.41 AKT1 APC BAX BRAF BUB1 BUB1B
7 cardiovascular system MP:0005385 10.4 AKT1 APC AXIN2 BRAF BUB1B CTNNB1
8 mortality/aging MP:0010768 10.4 AKT1 APC AXIN2 BAX BRAF BUB1
9 embryo MP:0005380 10.38 AKT1 APC AXIN2 BRAF BUB1B CTNNB1
10 endocrine/exocrine gland MP:0005379 10.37 AKT1 APC AXIN2 BAX BRAF BUB1
11 neoplasm MP:0002006 10.36 AKT1 APC BAX BRAF BUB1 BUB1B
12 digestive/alimentary MP:0005381 10.3 APC BRAF BUB1B CTNNB1 DCC EP300
13 integument MP:0010771 10.24 AKT1 APC AXIN2 BRAF BUB1B CTNNB1
14 craniofacial MP:0005382 10.21 APC AXIN2 BRAF CTNNB1 EP300 FGFR3
15 muscle MP:0005369 10.18 AKT1 APC BAX BRAF BUB1B CTNNB1
16 normal MP:0002873 10.18 AKT1 APC AXIN2 BRAF BUB1 CTNNB1
17 liver/biliary system MP:0005370 10.16 AKT1 APC BRAF BUB1 BUB1B CTNNB1
18 limbs/digits/tail MP:0005371 10.13 APC AXIN2 BAX BRAF CTNNB1 FGFR3
19 hearing/vestibular/ear MP:0005377 10.12 APC AXIN2 BAX BRAF CTNNB1 FGFR3
20 reproductive system MP:0005389 10.07 AKT1 APC AXIN2 BAX BRAF BUB1
21 no phenotypic analysis MP:0003012 10.03 AXIN2 BUB1 CTNNB1 FGFR3 NRAS PIK3CA
22 renal/urinary system MP:0005367 9.92 APC BAX BRAF CTNNB1 EP300 FGFR3
23 pigmentation MP:0001186 9.85 APC BRAF CTNNB1 DCC NRAS TP53
24 respiratory system MP:0005388 9.85 AKT1 BAX BRAF BUB1B CTNNB1 DCC
25 skeleton MP:0005390 9.73 AKT1 APC AXIN2 BAX BRAF BUB1B
26 vision/eye MP:0005391 9.4 APC AXIN2 BAX BRAF BUB1B CTNNB1

Drugs & Therapeutics for Colorectal Cancer

PubMed Health treatment related to Colorectal Cancer: 62

Surgery is performed to remove as much of the cancer as possible. In early stages, further treatment may not be needed. If the cancer is at a more advanced stage, further treatments like radiation therapy or chemotherapy are options.

Drugs for Colorectal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 783)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Methadone Approved Phase 4 76-99-3 4095
4
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
5
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
6
Orphenadrine Approved Phase 4 83-98-7 4601
7
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
8
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
9
Vitamin K1 Approved, Investigational Phase 4 84-80-0 5284607
10
Ferrous fumarate Approved Phase 4 141-01-5
11
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
12
Iron Approved Phase 4 7439-89-6 23925 29936
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
14
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
15
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
16
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
17
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
18
Acetaminophen Approved Phase 4 103-90-2 1983
19
Morphine Approved, Investigational Phase 4 57-27-2 5288826
20
Glucagon Approved Phase 4 16941-32-5
21
Magnesium oxide Approved Phase 4 1309-48-4 14792
22
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
23
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
24
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
25
Metronidazole Approved Phase 4 443-48-1 4173
26
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
27
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
28
Sodium citrate Approved, Investigational Phase 4 68-04-2
29
Magnesium citrate Approved Phase 4 3344-18-1
30
Tranexamic Acid Approved Phase 4 1197-18-8 5526
31
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
32
Azithromycin Approved Phase 4 83905-01-5 447043 55185
33
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
34
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
35
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
36
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
37
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
38
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
39
Rofecoxib Approved, Investigational, Withdrawn Phase 4 162011-90-7 5090
40
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
41
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
42
Chlorotrianisene Investigational, Withdrawn Phase 4 569-57-3 11289
43 Menaquinone Investigational Phase 4 1182-68-9
44 Cytochrome P-450 Enzyme Inhibitors Phase 4
45 Erythromycin Estolate Phase 4
46 Erythromycin stearate Phase 4
47 Erythromycin Ethylsuccinate Phase 4
48 Acetaminophen, hydrocodone drug combination Phase 4
49 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
50 Antitussive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 4794)
# Name Status NCT ID Phase Drugs
1 Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
2 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II Microsatellite-Stable or Low-Level Microsatellite-Instability Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
3 Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
4 TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial Unknown status NCT00868569 Phase 4
5 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
6 A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection. Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
7 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Unknown status NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
8 Study of New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
9 A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
10 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
11 Preoperative Assessment of Colon Tumor: A Prospective, Blinded Study. Unknown status NCT00114829 Phase 4
12 NK Activity Modulation by Intravenous Lidocaine During Laparoscopic Colorectal Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
13 Raltitrexed and Oxaliplatin and Lipiodol Transcatheter Arterial Chemoembolization for Advanced Colorectal Cancer Unknown status NCT01959061 Phase 4 Raltitrexed;Oxaliplatin;lipiodol
14 A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
15 Phase 4 of Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
16 Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
17 Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Unknown status NCT02575378 Phase 4 Metronimic chemotherapy plus Chinese Traditional Medicine;Metronimic chemotherapy
18 Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
19 A Prospective Evaluation of Capecitabine and Metabolite Pharmacokinetics in Elderly Breast and Colorectal Cancer Patients and Their Association With Toxicity and Molecular Markers of Enzyme Activity and Aging Unknown status NCT03465202 Phase 4 Capecitabine
20 Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough. Unknown status NCT02175914 Phase 4 Erythromycin
21 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
22 Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients With Advanced Colorectal or Gastric Cancer Treated With FOLFIRI Regimen Unknown status NCT01271582 Phase 4 Irinotecan, 5FU, leucovorin
23 Italian Multicenter Prospective Randomized Trial to Compare Additive Hemostatic Efficacy of EndoClot System to Prevent Bleeding After Endoscopic Mucosal Resection or Endoscopic Submucosal Dissection of Lesions in the Gastrointestinal Tract Unknown status NCT02688699 Phase 4
24 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
25 I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer Completed NCT00677586 Phase 4
26 Tandem Colonoscopy Study of Narrow Band Imaging Versus White Light Examination to Compare Neoplasia Miss Rates Completed NCT00628147 Phase 4
27 Study of Avastin in Combination With Chemotherapy for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases Completed NCT01972490 Phase 4 avastin;mFOLFOX6
28 MR Colonography With Fecal Tagging: A Prospective, Randomized Study Completed NCT00114842 Phase 4
29 MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil Completed NCT00332943 Phase 4
30 The Effect of Darbepoetin Alfa Treatment Upon the Rehabilitation Following Planned Surgery for Colorectal Cancer Completed NCT00122720 Phase 4 Darbepoetin Alfa
31 Preoperative Assessment for Synchronous Carcinoma or Polyps With MR Colonography in Patients With Obstructing Cancer. A Prospective Study. Completed NCT00300547 Phase 4
32 A Prospective, Randomized, Control Trial of Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles vs 12 Cycles Completed NCT00868816 Phase 4 12 cycles of oxaliplatine based adjuvant chemotherapy;8 cycles of oxaliplatine based adjuvant chemotherapy
33 Postoperative folfox4 Only vs folfox4 Plus TAC in the Treatment Unresectable Liver Metastasis of Colorectal Cancer: a Randomized,Prospective,Control Trial Completed NCT00869271 Phase 4
34 STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea Completed NCT00050635 Phase 4 Sandostatin LAR Depot
35 An Open Label Study to Evaluate the Safety of Xeloda as Adjuvant Monotherapy in Patients Who Have Undergone Surgery for Colon Cancer, Dukes Stage C. Completed NCT00502671 Phase 4 capecitabine [Xeloda]
36 Contribution to the Study of Inflammatory Response in Laparoscopic vs Open Colon Cancer Surgery Completed NCT00942461 Phase 4
37 Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV Completed NCT00263055 Phase 4 oxaliplatin
38 Endo-Laparoscopic Approach Versus Conventional Open Surgery in the Management of Obstructing Left-sided Colon Cancer: A Randomized Trial Completed NCT00654212 Phase 4
39 The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) or Gastrointestinal Stromal Tumour (GIST) Completed NCT02800330 Phase 4 Esomeprazole 40mg concomitantly;Esomeprazole 40mg before;Regorafenib 160mg or 120mg
40 An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin™) Completed NCT01588990 Phase 4 Oxaliplatin;Capecitabine;Bevacizumab;Leucovorin;5-Fluouracil;Irinotecan
41 Multi-center, Randomized Comparison Study to eVALUatE Outcomes and Resource Needs of Imaging and Treatment Following Primovist-enhanced MRI of the Liver in Comparison to Extracellular Contrast Media (ECCM)-Enhanced MRI and Contrast-enhanced Computed Tomography (CT) in Patients With a History of Colorectal Cancer and Known or Suspected Metachronous Liver Metastases. Completed NCT00764621 Phase 4
42 Clinical Efficacy of Chemotherapy Combined With Cytokine-induced Killer in Treatment of Patients With Colon Cancer Completed NCT03084809 Phase 4 Cytokine-induced killer cells+ FOLFOX4;FOLFOX4
43 Effect of Intravenous Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function in Patients With Colon Cancer Completed NCT02231203 Phase 4 Omegaven;Placebo
44 A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy Completed NCT01170754 Phase 4 PEG-3350 and Gatorade;Golytely 4 liters
45 Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery Completed NCT02314871 Phase 4 Piritramide;Morphine
46 Patient Satisfaction With Propofol for Out Patient Colonoscopy: A Prospective, Randomized, Double-Blind Study Completed NCT02937506 Phase 4 Propofol;Fentanyl Plus Midazolam
47 Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial Completed NCT02078726 Phase 4 Glucagon;Placebo
48 Effect of Postoperative Laxative on Bowel Function After Colonic Surgery Completed NCT00427492 Phase 4 Magnesia;Placebo
49 Does Hemodynamic Optimization During and After Colorectal Surgery Result in Improved Intestinal Perfusion, Sustained Intestinal Barrier and Improved Postoperative Recovery? Completed NCT01175317 Phase 4
50 Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX' Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda

Search NIH Clinical Center for Colorectal Cancer

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aldesleukin
capecitabine
Carmustine
Floxuridine
Fluorouracil
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
irinotecan
Irinotecan hydrochloride
Levamisole
Lomustine
oxaliplatin
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
regorafenib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Colorectal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Colorectal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Colorectal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: colonic neoplasms

Genetic Tests for Colorectal Cancer

Genetic tests related to Colorectal Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Colon 29
2 Colorectal Cancer 29 AKT1 APC AURKA AXIN2 BAX BRAF BUB1 BUB1B CCND1 CTNNB1 DCC DLC1 EP300 FGFR3 FLCN MCC MLH3 NRAS PDGFRL PIK3CA PLA2G2A PTPN12 PTPRJ RAD54B SRC TLR2 TP53
3 Colorectal Cancer, Susceptibility to 29

Anatomical Context for Colorectal Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Colorectal Cancer:

19
Colon, Rectum

MalaCards organs/tissues related to Colorectal Cancer:

40
Colon, Liver, Lymph Node, Breast, Lung, T Cells, Endothelial

Publications for Colorectal Cancer

Articles related to Colorectal Cancer:

(show top 50) (show all 66005)
# Title Authors PMID Year
1
Loss-of-function mutations in PPAR gamma associated with human colon cancer. 61 6 57 54
10394368 1999
2
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 6 61 57
22281684 2012
3
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 6 57 54
12198537 2002
4
Comprehensive molecular characterization of human colon and rectal cancer. 6 57
22810696 2012
5
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. 6 57
22722830 2012
6
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. 57 6
22270724 2012
7
Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. 57 6
16879199 2006
8
Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. 6 57
16407113 2006
9
Colorectal cancer: mutations in a signalling pathway. 57 6
16094359 2005
10
High frequency of mutations of the PIK3CA gene in human cancers. 6 57
15016963 2004
11
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. 6 54 61
19881948 2009
12
Functional analysis of PIK3CA gene mutations in human colorectal cancer. 61 6 54
15930273 2005
13
APC I1307K increases risk of transition from polyp to colorectal carcinoma in Ashkenazi Jews. 6 61 54
11159880 2001
14
Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients. 6 61
32000721 2020
15
The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer. 61 6
27165003 2016
16
GREM1 and POLE variants in hereditary colorectal cancer syndromes. 6 61
26493165 2016
17
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. 61 6
26623049 2015
18
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. 6 61
25989278 2015
19
GREM1 germline mutation screening in Ashkenazi Jewish patients with familial colorectal cancer. 6 61
25992589 2015
20
TP53 loss creates therapeutic vulnerability in colorectal cancer. 61 57
25901683 2015
21
HD chromoendoscopy coupled with DNA mass spectrometry profiling identifies somatic mutations in microdissected human proximal aberrant crypt foci. 6 61
24651453 2014
22
Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer. 6 61
24861525 2014
23
BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. 61 6
24594804 2014
24
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. 61 6
23251002 2013
25
Recurrent R-spondin fusions in colon cancer. 57 61
22895193 2012
26
Colorectal adenomas and cancer link to chromosome 13q22.1-13q31.3 in a large family with excess colorectal cancer. 57 61
20522424 2010
27
Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. 61 47 54
19926638 2010
28
Microsatellite instability in colorectal cancer-the stable evidence. 54 57
20142816 2010
29
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. 6 61
20233444 2010
30
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. 6 61
20350999 2010
31
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. 54 47 61
19734943 2009
32
PIK3CA mutations predict local recurrences in rectal cancer patients. 6 54
19903786 2009
33
Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. 47 61 54
19391107 2009
34
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. 6 54
19366826 2009
35
A mitochondrial DNA mutation linked to colon cancer results in proton leaks in cytochrome c oxidase. 61 6
19218458 2009
36
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. 54 6
19223544 2009
37
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. 6 54
19114683 2009
38
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. 54 6
19679400 2009
39
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. 54 6
19001320 2008
40
Prevalence of mutations in APC, CTNNB1, and BRAF in Tunisian patients with sporadic colorectal cancer. 54 6
18992635 2008
41
Deregulated expression of miR-106a predicts survival in human colon cancer patients. 54 47 61
18521848 2008
42
Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). 54 6
18186519 2008
43
Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. 54 47 61
17827156 2007
44
Similar colorectal cancer risk in patients with monoallelic and biallelic mutations in the MYH gene identified in a population with adenomatous polyposis. 54 6
17949294 2007
45
Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. 47 54 61
16609010 2006
46
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. 6 54
16618717 2006
47
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. 54 6
16015629 2005
48
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 54 6
15608678 2005
49
Mutation of the PIK3CA gene in ovarian and breast cancer. 6 54
15520168 2004
50
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. 54 6
15342696 2004